JAK1 and neoplasm: In patients receiving immunotherapy, tumor cells can downregulate or alter IFN-γ signaling pathways such as loss-of-function alleles of genes encoding for JAK1/2 and changes in STAT1 to escape the influence of IFN-γ (37), resulting in resistance.